Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 7/20 | 0.50 |
| ▸ | ATP4B | P51164 | 7/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.50 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179008 | 0.95 | ATP4A (0.51) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL3170087 | 0.94 | ATP4A (0.50) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL29694095 | 0.94 | ATP4A (0.55) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL537800 | 0.94 | ATP4A (0.55) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL3177079 | 0.93 | ATP4A (0.50) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL3177754 | 0.92 | CYP2C9 (0.48) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL3170779 | 0.88 | CYP2C9 (0.49) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL14433017 | 0.87 | CYP2C9 (0.50) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL13846375 | 0.87 | CYP2C9 (0.65) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL29693616 | 0.87 | CYP2C9 (0.65) | ATP4AATP4BCYP2C9CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | TAKEDA GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2008-06-19 | — | — | US | claimed |
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | NYCOMED GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | TAKEDA GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-7601737-B2 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1912947-A1 | ISOTOPICALLY SUBSTITUTED PANTOPRAZOLE | Nycomed GmbH (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910293-A1 | ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS | Nycomed GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012651-A1 | ISOTOPICALLY SUBSTITUTED PANTOPRAZOLE | NYCOMED GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012650-A1 | ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS | NYCOMED GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | ATP4A 71/4885ATP4B 117/4885CYP2C9 100/4885 |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | SLC10A2, CYP2J2, CYP2D6 | ATP4A 1320/4885ATP4B 1679/4885CYP2C9 81/4885 |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | ATP4A 71/4885ATP4B 117/4885CYP2C9 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.